Clinical and laboratory specific parameters of COVID-19 in patients with TB/HIV co-infection
https://doi.org/10.21292/2075-1230-2022-100-4-14-21
Abstract
The objective: to study clinical and laboratory specific parameters of the COVID-19 course in patients with TB/HIV co-infection, to analyze changes in the lungs caused by COVID-19 in patients with pulmonary tuberculosis and concurrent HIV infection.
Subjects and Methods. 68 HIV-infected patients aged 18-66 years old were included in the study, they all were admitted to the Novosibirsk State Regional Clinical Tuberculosis Hospital, Novosibirsk, with confirmed COVID-19 from May 2020 to May 2021. Clinical manifestations, CD4 count and HIV RNA level, and the presence of secondary infections were assessed.
Results. In patients with severe and profound immunodeficiency, coronavirus infection was more often mild to moderate, and in immunocompetent patients – moderate to severe. However, patients with profound immunodeficiency were at greater risk of an adverse outcome due to lymphohematogenic progression of tuberculosis and concurrent opportunistic infections.
Conclusion. When diagnosing and treating COVID-19 in patients with comorbid HIV infection and tuberculosis, it is important to consider the form of tuberculosis and CD4+ count.
About the Authors
R. S. AlzhanovRussian Federation
Rustam S. Alzhanov, Head of Department for Treatment of Patients
with Tuberculosis and COVID-19, Thoracic Surgeon
14, Vavilova St., Novosibirsk, 630082
A. V. Pyatibratova
Russian Federation
Anna V. Pyatibratova, Head Physician
14, Vavilova St., Novosibirsk, 630082
Phone/Fax: + 7 (383) 225-59-81
D. V. Krasnov
Russian Federation
Denis V. Krasnov, Doctor of Medical Sciences, Deputy Chief Physician for Surgery
14, Vavilova St., Novosibirsk, 630082
D. V. Kapustin
Russian Federation
Dmitriy V. Kapustin, Candidate of Medical Sciences, Assistant of Infections Diseases Department
40, Semyi Shamshinykh St., Novosibirsk, 630099
Phone/Fax: + 7 (383) 218-19-95
S. V. Anufriev
Russian Federation
Sergey V. Anufriev, Anesthesiologist and Emergency Physician of Department for Treatment of Patients with Tuberculosis and COVID-19
14, Vavilova St., Novosibirsk, 630082
40, Semyi Shamshinykh St., Novosibirsk, 630099
References
1. Ekaterincheva O.L., Malkova А.M., Karev V.E., Kudryavtsev I.V., Zinchenko Yu.S., Potepun T.B., Kudlay D.А., Starshinova А.А. Specific parameters of tuberculosis diagnostics in case of concurrent COVID-19. Journal Infektologii, 2021, vol. 13, no. 1, pp. 117-123. (In Russ.)
2. Mishina А.V., Mishin V.Yu., Ergeshov А.E., Sobkin А.L., Sergeeva N.V., Pilipenko S.V., Romanov V.V. New coronoviral infection (COVID-19) combined with tuberculosis in patients at late stages of HIV infection with immunodeficiency. VICH-Infektsiya i Immunosupressii, 2021, vol. 13, no. 1, pp. 80-87. (In Russ.) https://doi.org/10.22328/2077-9828-2021-13-1-80-87.
3. Starshinova А.А., Malkova А.M., Starshinova А.А., Karev V.E., Kudlay D.А., Dovgalyuk I.F. Tuberculosis under conditions of novel coronavirus infection. Pediatriya. Journal im. G.N. Speranskogo, 2021, vol. 100, no. 2, pp. 153-156. (In Russ.)
4. Testov V.V., Sterlikov S.А., Vasilyeva I.А., Sidorova I.А., Mikhaylova Yu.V. Federal Register of TB Cases as a tool for monitoring the impact of COVID-19 pandemic response activities on the TB care system. Tuberculosis and Lung Diseases, 2020, vol. 98, no. 11, pp. 6-11. (In Russ.) https://doi.org/10.21292/2075-1230-2020-98-11-6-11.
5. Agarwal-Jans S. Timeline: HIV. Cell, 2020, vol. 183, no. 2, pp. 550. doi: 10.1016/j.cell.2020.09.004. PMID: 33064990.
6. Bouaré F., Laghmari M., Etouche F.N., Arjdal B., Saidi I., Hajhouji F., Ghannane H., Amro L., Tassi N., Benali S.A. Unusual association of COVID-19, pulmonary tuberculosis and human immunodeficiency virus, having progressed favorably under treatment with chloroquine and rifampin. Pan. Afr. Med. J., 2020, no. 35, suppl. S2, 110. [Google Scholar].
7. Cribbs S.K., Crothers K., Morris A. Pathogenesis of HIV-related lung disease: immunity, infection, and inflammation. Physiol. Rev., 2020, no. 100, pp. 603-632. [Google Scholar].
8. Farias L.A.B.G., Moreira A.L.G., Corrêa E.A., de Oliveira Lima C.A.L., Lopes I.M.P., de Holanda P.E.L., Nunes F.R., Neto R.D.J.P. Case report: coronavirus disease and pulmonary tuberculosis in patients with human immunodeficiency virus: report of two cases. Am. J. Trop. Med. Hyg., 2020, no. 103, pp. 1593-1596. [Google Scholar].
9. Global Tuberculosis Report 2021. World Health Organization. Geneva, 2021, 44 p.
10. Khanal S., Schank M., El Gazzar M., Moorman J.P., Yao Z.Q. HIV-1 latency and viral reservoirs: existing reversal approaches and potential technologies, targets, and pathways involved in HIV latency studies. Cells, 2021, vol. 10, no. 2, pp. 475. doi: 10.3390/cells10020475.
11. Kumar R., Bhattacharya D.B., Meena D.V. et al. COVID-19 and TB co-infection- ’Finishing touch”in perfect recipe to’severity’or ‘death’. J. Infection, 2020, vol. 81, no. 3, pp. e39-e40. doi:10.1016/j.jinf.2020.06.062.
12. Marcus J.L., Chao C.R., Leyden W.A., Xu L., Quesenberry C.P., Jr., Klein D.B., Towner W.J., Horberg M.A., Silverberg M.J. Narrowing the gap in life expectancy between HIV-infected and HIV-uninfected individuals with access to care. J. Acquir. Immune Defic. Syndr., 2016, no. 73, pp. 39-46. [Google Scholar].
13. Nagarakanti S.R., Okoh A.K., Grinberg S. et al. Clinical outcomes of patients with COVID‐19 and HIV coinfection. J. Med. Virol., 2021, vol. 93, no. 3, pp. 1687-1693. doi:10.1002/jmv.26533.
14. Ortiz-Martínez Y., Mogollón-Vargas J.M., López-Rodríguez M., Rodriguez-Morales A.J. A fatal case of triple coinfection: COVID-19, HIV and tuberculosis. Travel Med. Infect. Dis., 2021, September-October, 43. 102129, Published online 2021 Jun 24. doi: 10.1016/j.tmaid.2021.102129.
15. Rivas N., Espinoza M., Loban A., Luque O., Jurado J., Henry-Hurtado N., Goodridge A. Case report: COVID-19 recovery from triple infection with Mycobacterium tuberculosis, HIV, and SARS-CoV-2. Am. J. Trop. Med. Hyg., 2020, no. 103, pp. 1597-1599. [Google Scholar].
16. Romani B., Allahbakhshi E. Underlying mechanisms of HIV-1 latency. Virus Genes, 2017, no. 53, pp. 329-339. [Google Scholar].
17. Swaminathan S., Nagendran G. HIV and tuberculosis in India. J. Biosci., 2008, vol. 33, no. 4, pp. 527-537. [PubMed] [Article] [Google Scholar].
18. Teeraananchai S., Kerr S.J., Amin J., Ruxrungtham K., Law M.G. Life expectancy of HIV-positive people after starting combination antiretroviral therapy: A meta-analysis. HIV Med., 2017, no. 18, pp. 256-266. [Google Scholar].
19. Terahara K., Iwabuchi R., Iwaki R., Takahashi Y., Tsunetsugu-Yokota Y. Substantial induction of non-apoptotic CD4 T-cell death during the early phase of HIV-1 infection in a humanized mouse model. Microbes. Infect., 2021, vol. 23, no. 1, pp. 104767. doi: 10.1016/j.micinf.2020.10.003. Epub 2020 Oct 10. PMID: 33049386.
20. Tingxia Lv, Wei Cao, Taisheng Li. HIV-related immune activation and inflammation: current understanding and strategies. J. Immun. Res., vol. 2021, Article ID 7316456, 13 p. 29 September 2021 https://doi.org/10.1155/2021/7316456.
21. UNAIDS. Global HIV & AIDS statistics — Fact sheet. https://www.unaids.org/ru/resources/fact-sheet.
22. WHO, 2020. Discurso de abertura do Diretor-Geral da OMS na conferência de imprensa sobre COVID-19. Geneva, Switzerland, World Health Organization; Available at: https://www.who.int/es/dg/speeches/detail/who-director-general-sopening-remarks-at-the-media-briefing-oncovid-19-11-march-2020. Accessed March 26, 2020. [Google Scholar].
23. Zhang Q., Frange P., Blanche S., Casanova J.L. Pathogenesis of infections in HIV-infected individuals: Insights from primary immunodeficiencies. Curr. Opin. Immunol., 2017, no. 48, pp. 122-133. [CrossRef].
24.
Review
For citations:
Alzhanov R.S., Pyatibratova A.V., Krasnov D.V., Kapustin D.V., Anufriev S.V. Clinical and laboratory specific parameters of COVID-19 in patients with TB/HIV co-infection. Tuberculosis and Lung Diseases. 2022;100(4):14-21. (In Russ.) https://doi.org/10.21292/2075-1230-2022-100-4-14-21